Your browser doesn't support javascript.
loading
Urinary peptides in heart failure: a link to molecular pathophysiology.
He, Tianlin; Mischak, Michaela; Clark, Andrew L; Campbell, Ross T; Delles, Christian; Díez, Javier; Filippatos, Gerasimos; Mebazaa, Alexandre; McMurray, John J V; González, Arantxa; Raad, Julia; Stroggilos, Rafael; Bosselmann, Helle S; Campbell, Archie; Kerr, Shona M; Jackson, Colette E; Cannon, Jane A; Schou, Morten; Girerd, Nicolas; Rossignol, Patrick; McConnachie, Alex; Rossing, Kasper; Schanstra, Joost P; Zannad, Faiez; Vlahou, Antonia; Mullen, William; Jankowski, Vera; Mischak, Harald; Zhang, Zhenyu; Staessen, Jan A; Latosinska, Agnieszka.
Afiliação
  • He T; Mosaiques Diagnostics GmbH, Hannover, Germany.
  • Mischak M; Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University Hospital, Aachen, Germany.
  • Clark AL; Mosaiques Diagnostics GmbH, Hannover, Germany.
  • Campbell RT; Academic Cardiology Department, Hull York Medical School in the University of Hull, Kingston upon Hull, UK.
  • Delles C; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Díez J; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Filippatos G; Program of Cardiovascular Diseases, CIMA Universidad de Navarra, IdiSNA and CIBERCV, Pamplona, Spain.
  • Mebazaa A; Departments of Nephrology and Cardiology, Clínica Universidad de Navarra, Pamplona, Spain.
  • McMurray JJV; Heart Failure Unit, Department of Cardiology, Athens University Hospital Attikon, Athens, Greece.
  • González A; Université de Paris, Unité Inserm MASCOT, Department of Anaesthesiology and Intensive Care, Saint Louis-Lariboisière - Fernand Widal University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.
  • Raad J; F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
  • Stroggilos R; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Bosselmann HS; Program of Cardiovascular Diseases, CIMA Universidad de Navarra, IdiSNA and CIBERCV, Pamplona, Spain.
  • Campbell A; Mosaiques Diagnostics GmbH, Hannover, Germany.
  • Kerr SM; Biotechnology Division, Biomedical Research Foundation, Academy of Athens, Athens, Greece.
  • Jackson CE; Department of Cardiology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.
  • Cannon JA; Centre for Genomic and Experimental Medicine, Institute of Genetics & Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.
  • Schou M; MRC Human Genetics Unit, Institute of Genetics & Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.
  • Girerd N; Queen Elizabeth University Hospital, Glasgow, UK.
  • Rossignol P; Harefield Hospital, Harefield, London, UK.
  • McConnachie A; Herlev-Gentofte Hospital, Department of Cardiology, Herlev, Denmark.
  • Rossing K; Université de Lorraine, Inserm, Centre d'Investigations Cliniques- Plurithématique 1433, and Inserm 1116 DCAC, CHRU de Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
  • Schanstra JP; Université de Lorraine, Inserm, Centre d'Investigations Cliniques- Plurithématique 1433, and Inserm 1116 DCAC, CHRU de Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
  • Zannad F; Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
  • Vlahou A; Department of Cardiology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.
  • Mullen W; Institut National de la Santé et de la Recherche Médicale, U1048, Institute of Cardiovascular and Metabolic Disease, Toulouse, France.
  • Jankowski V; Université de Lorraine, Inserm, Centre d'Investigations Cliniques- Plurithématique 1433, and Inserm 1116 DCAC, CHRU de Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
  • Mischak H; Biotechnology Division, Biomedical Research Foundation, Academy of Athens, Athens, Greece.
  • Zhang Z; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Staessen JA; Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University Hospital, Aachen, Germany.
  • Latosinska A; Mosaiques Diagnostics GmbH, Hannover, Germany.
Eur J Heart Fail ; 23(11): 1875-1887, 2021 11.
Article em En | MEDLINE | ID: mdl-33881206
ABSTRACT

AIMS:

Heart failure (HF) is a major public health concern worldwide. The diversity of HF makes it challenging to decipher the underlying complex pathological processes using single biomarkers. We examined the association between urinary peptides and HF with reduced (HFrEF), mid-range (HFmrEF) and preserved (HFpEF) ejection fraction, defined based on the European Society of Cardiology guidelines, and the links between these peptide biomarkers and molecular pathophysiology. METHODS AND

RESULTS:

Analysable data from 5608 participants were available in the Human Urinary Proteome database. The urinary peptide profiles from participants diagnosed with HFrEF, HFmrEF, HFpEF and controls matched for sex, age, estimated glomerular filtration rate, systolic and diastolic blood pressure, diabetes and hypertension were compared applying the Mann-Whitney test, followed by correction for multiple testing. Unsupervised learning algorithms were applied to investigate groups of similar urinary profiles. A total of 577 urinary peptides significantly associated with HF were sequenced, 447 of which (77%) were collagen fragments. In silico analysis suggested that urinary biomarker abnormalities in HF principally reflect changes in collagen turnover and immune response, both associated with fibrosis. Unsupervised clustering separated study participants into two clusters, with 83% of non-HF controls allocated to cluster 1, while 65% of patients with HF were allocated to cluster 2 (P < 0.0001). No separation based on HF subtype was detectable.

CONCLUSIONS:

Heart failure, irrespective of ejection fraction subtype, was associated with differences in abundance of urinary peptides reflecting collagen turnover and inflammation. These peptides should be studied as tools in early detection, prognostication, and prediction of therapeutic response.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca Tipo de estudo: Guideline / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca Tipo de estudo: Guideline / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article